肝细胞癌（HCC）是全球癌症相关死亡的重要原因。对于早期诊断的少数病人，有可治愈的治疗方法；然而，仅有少数多激酶抑制剂在晚期病例中有效，凸显了对新型治疗靶点的需求。其中一个潜在的靶点是蛋白质精氨酸甲基转移酶（PRMT），其催化多种精氨酸甲基化形式，在各种癌症中常常过表达。然而，PRMTs在HCC中的多样表达模式和临床价值尚不明确。在本研究中，我们利用公开可得的数据集，评估了HCC队列中PRMTs的转录表达。我们的结果表明PRMTs与HCC患者的预后存在显著关联，且这些患者具有不同的临床特征和背景。这突显了PRMTs作为HCC患者预测生物标志物的潜在潜力。特别地，单细胞RNA测序分析结合另一个人类队列研究突显了PRMT1在HCC进展中的关键作用，特别是在Tex的背景下。将这些发现转化为具体的治疗决策可能满足HCC患者未满足的治疗需求。

HCC is a major contributor to cancer-related mortality worldwide. Curative treatments are available for a minority of patients diagnosed at early stages; however, only a few multikinase inhibitors are available and are marginally effective in advanced cases, highlighting the need for novel therapeutic targets. One potential target is the protein arginine methyltransferase, which catalyzes various forms of arginine methylation and is often overexpressed in various cancers. However, the diverse expression patterns and clinical values of PRMTs in HCC remain unclear. In the present study, we evaluated the transcriptional expression of PRMTs in HCC cohorts using publicly available datasets. Our results revealed a significant association between PRMTs and prognosis in HCC patients with diverse clinical characteristics and backgrounds. This highlights the promising potential of PRMTs as prognostic biomarkers in patients with HCC. In particular, single-cell RNA (scRNA) sequencing analysis coupled with another human cohort study highlighted the pivotal role of PRMT1 in HCC progression, particularly in the context of Tex. Translating these findings into specific therapeutic decisions may address the unmet therapeutic needs of patients with HCC.